help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ouyang, H.
Right arrow Articles by Somerman, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ouyang, H.
Right arrow Articles by Somerman, M. J.
Endocrinology Vol. 141, No. 12 4671-4680
Copyright © 2000 by The Endocrine Society

ARTICLES

Parathyroid Hormone-Related Protein Down-Regulates Bone Sialoprotein Gene Expression in Cementoblasts: Role of the Protein Kinase A Pathway1

Hongjiao Ouyang, Renny T. Franceschi, Laurie K. McCauley, Dian Wang and Martha J. Somerman

Departments of Periodontics/Prevention/Geriatrics (H.O., R.T.F., L.K.M., D.W., M.J.S.), and Restorative Sciences/Cardiology/Endodontics (H.O.), School of Dentistry, Departments of Biochemistry (R.T.F.), and Pharmacology (M.J.S.), School of Medicine, The University of Michigan, Ann Arbor, Michigan 48109-1078

Address all correspondence and requests for reprints to: Hongjiao Ouyang, D.D.S., Ph.D., Departments of Periodontics/Prevention/Geriatrics and Restorative Sciences/Cardiology/Endodontics, The University of Michigan, 1011 North University Avenue, Ann Arbor, Michigan 48109-1078. E-mail: hongjiao{at}umich.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
PTH-related protein (PTHrP) acts as a paracrine and/or autocrine regulator of cell proliferation, apoptosis, and differentiation and is implicated in tooth development. The current studies employed cementoblasts to determine the role(s) and mechanisms of PTHrP in regulating cementum formation. Results demonstrated that PTHrP repressed gene expression and protein synthesis of bone sialoprotein (BSP) and abolished cementoblast-mediated biomineralization in vitro. The BSP gene inhibition required protein synthesis. The PTHrP analog (1–31) and other activators of the PKA pathway (3-isobutyl-1-methylxathine (IBMX), forskolin (FSK) and Sp-Adenosine-3', 5'-cyclic monophosphorothioate (Sp-cAMPss) also down-regulated BSP gene expression and blocked cementoblast-mediated biomineralization. In contrast, the PTHrP analog (7–34), a PTHrP antagonist, and the activators of the PKC pathway [phorbol 12-myristate 13-acetate (PMA) and phorbol 12, 13-dibutyrate (PDBu)] promoted BSP gene expression. In addition, the PKA pathway inhibitor (9-(2-tetrahydrofuryl) adenine (THFA) partially, but significantly reversed the PTHrP-mediated down-regulation of BSP gene expression. Furthermore, THFA alone significantly increased BSP messenger RNA (mRNA) expression in cementoblasts. In contrast, the inhibitor of the PKC pathway (GF109203X) did not reverse the PTHrP inhibitory effect on BSP gene expression. Furthermore, GF109203X alone dramatically reduced the BSP transcript levels. These data indicate that the cAMP/PKA pathway mediates the PTHrP-mediated down-regulation of BSP mRNA expression in cementoblasts; and furthermore, this pathway may, through an intrinsic inhibition mechanism, regulate the basal level of BSP mRNA expression. In contrast, the activation of PKC promotes BSP gene expression. These data provide new insights into the molecular mechanisms involved in PTHrP regulation of cementogenesis.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
PTH-RELATED PROTEIN (PTHrP) was initially isolated and cloned from tumors due to its PTH-like properties and resultant humoral hypercalcemia of malignancy (1, 2). Subsequently, it was recognized that PTHrP is associated with a variety of normal tissues/organs and acts as an important autocrine and/or paracrine factor of cell proliferation, apoptosis, and differentiation (3). Overexpression of PTHrP in chondrocytes in vivo causes a delay in their differentiation and in mineralization of cartilage (4). In contrast, but consistent with these findings, disruption of either PTHrP (5) or PTH-1 receptor (6) genes leads to an accelerated differentiation of chondrocytes. These studies demonstrated that PTHrP plays a pivotal role in regulating formation of the skeletal tissues. Although the regulatory functions of PTHrP during the development of the skeletal system have been well established, the role of PTHrP in regulating other mineralized tissues, such as those associated with teeth, is poorly understood. Tooth-related mineralized tissues differ from bone in many aspects, such as histological features and physiological function (7). Therefore, understanding the role of PTHrP in controlling formation and maintenance of these tooth-related mineralized tissues will expand the knowledge of regulatory mechanisms involved in PTHrP effects on mineralized tissue formation.

Cementum is a thin mineralized tissue covering the tooth root surface. It differs from bone in that it lacks innervation and vascularization (7). Furthermore, cementum has limited remodeling potential when compared with bone (7). The unique functions of cementum are related to its role as an important component of the periodontal attachment apparatus (the periodontium), anchoring teeth to the surrounding alveolar bone, and thereby contributing to the maintenance of structural stability and physiologic function of the dentition. Although cementum has these important functions, the molecular mechanisms involved in regulating the formation of cementum remain largely unknown. Accumulating evidence indicates that PTHrP may serve as a critical paracrine and/or autocrine regulator of cementogenesis. These findings include 1) during cementogenesis, PTHrP is produced by cells associated with the periodontium, such as Hertwig’s epithelial cells, osteoblasts lining the surrounding alveolar bone, and cementoblasts themselves (8); 2) cementoblasts possess PTH/PTHrP receptors (9, 10); and 3) PTHrP deficiency of certain stains of PTHrP knock-out mice results in the failure of tooth eruption and in fusion of cementum with surrounding alveolar bone (11). To further elucidate the function of PTHrP in cementogenesis, it is important to determine how PTHrP regulates cementoblast activities, such as their gene expression and biomineralization ability. The current studies focus on identifying the signal transduction pathways underlying PTHrP regulation of cementoblast gene expression in vitro.

It is well established that PTHrP and PTH interact with a G protein-coupled receptor, the PTH-1 receptor. The PTH-1 receptor-G protein complex activates two well-defined signal transduction pathways (12). Activation of adenylyl cyclase and phospholipase C leads to production of cAMP, inositol phosphates (IPs) and diacylglycerol (DAG), respectively. These intracellular mediators ultimately exert their functions through activation of various protein kinase complexes, notably, protein kinase A (PKA) by cAMP and protein kinase C (PKC) by DAG. PKA and PKC complexes can subsequently phosphorylate specific transcription factors and consequently affect transcription of specific genes. PKA mainly targets members of the cAMP response element binding protein families (CREBs and ATF members), whereas PKC mainly acts on members of the AP-1 family. The selective stimulation of PKA and/or PKC pathways and the resulting specific activation of transcription factors generates the diversity of actions by which different genes, i.e. extracellular matrix molecules, may be regulated in a tissue/cell type-specific manner in response to PTH/PTHrP.

The immortalized cementoblast cell lines used in the current study were obtained from tooth root surfaces of OC-TAg transgenic mice, which carry an osteocalcin promoter driving the SV-40 large T antigen gene to ensure the selective immortalization of OCN expressing cells (13, 14). We have shown that these cementoblast cell lines closely resemble their in vivo counterparts in many properties, such as gene expression and ability to mineralize. Relevant to the current study is that these cementoblast cell lines express PTH-1 receptor messenger RNA (mRNA), and exhibit a PTHrP-induced cAMP elevation and c-fos gene expression, thereby providing an in vitro model to study the effects of PTHrP on cementoblast activity (15). Moreover, PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) represses the expression of cementum-associated gene markers in these cells, such as BSP, OCN, and type I collagen (15). BSP was selected for the current studies because 1) the temporo-spatial gene expression pattern of BSP closely correlates with the initiation of cementum and bone formation (16, 17); and 2) BSP protein is thought to play a critical role in promoting biomineralization (18, 19, 20). The current investigation focused on determining the molecular mechanisms underlying PTHrP’s effect on BSP gene expression in cementoblasts in vitro.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture and experimental design
The cementoblast cell line, OC-CM 30 (15), was cultured in DMEM (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% FBS (Life Technologies, Inc.), 100 U/ml penicillin and 100 g/ml streptomycin (BioWhittaker, Inc., Walkersville, MD) in a humidified atmosphere of 5% CO2 at 37 C. This clonal population was selected for the current studies based on its robust expression of PTH-1 receptor mRNA and responses to PTH/PTHrP stimulation, in vitro (15).

Dose-dependent effect of PTHrP
Cementoblasts were plated as described above, and upon confluence, were treated with PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (Bachem California, Inc., Torrance, CA) at concentrations ranging from 10-13 M to 10-6 M for 24 h. At these doses, cell viability was maintained as monitored by morphological observation and by cell proliferation assay (data not shown). To determine steady-state BSP mRNA levels, total RNA was isolated from PTHrP- and vehicle- (1 mg/ml bovine albumin/4 mM HCl) treated cultures and analyzed by Northern blotting. At the doses of PTHrP used for these studies, cell viability was maintained.

Time-course experiment
To determine the temporal effect of PTHrP on BSP mRNA expression, cementoblasts were plated at 5 x 104 cells/cm2 in 100-mm tissue culture plates and grown in DMEM media as described above. At confluence (designated as 0 h), cells were treated with human PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (10-7 M) (hPTHrP, Bachem California, Inc.) and total RNA extracted at 0, 2, 6, 12, and 24 h for determination of the steady-state BSP mRNA levels by Northern blot analysis. The specific dose of PTHrP was selected due to its prominent inhibition of BSP gene expression.

Effect of cycloheximide
The effect of cycloheximide (Sigma, St. Louis, MO) (21) on PTHrP-mediated inhibition of BSP gene expression was also determined. Confluent cementoblasts were exposed to either vehicle, or 10-7 M PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34), or 10-7 M PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) plus cycloheximide (10 µg/ml), or cycloheximide (10 µg/ml) alone for 9 h, followed by total RNA extraction and Northern blot analysis to measure steady-state BSP mRNA levels.

Effect of actinomycin D
To determine whether PTHrP affects the stability of BSP mRNA, the decay rates of BSP mRNA in vehicle- and PTHrP-pretreated groups were measured. Confluent cementoblasts were pretreated with either vehicle or PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (10-7 M) for 6 h before transcription inhibition. Then, media were removed and cells were stimulated with vehicle or PTHrP (10-7 M), either in the presence or in the absence of actinomycin D (Sigma, 1 µg/ml), an inhibitor of transcription (22), for designated time intervals (0, 3, 6, 9, and 12 h). Total RNA was harvested and Northern blot analysis performed to follow the decay course of BSP mRNA associated with different treatment conditions. Data are presented as logarithmic values of mean ± SD of cpm of BSP mRNA after being normalized to 18S rRNA.

Dissection of signal transduction pathway(s)
Three strategies were employed to identify the signal transduction pathway(s) involved in PTHrP regulation.

First, the effect of PTHrP analogs on BSP mRNA expression was examined. Confluent cementoblasts were treated with human PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31), or (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34), or (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (Bachem California, Inc.) (23) at a concentration of 10-7 M for 24 h and total RNA was extracted for Northern blot analysis.

In a parallel approach, the effects of various activators of PKA/PKC pathways on BSP mRNA expression in cementoblasts were analyzed. At confluence, cementoblasts were treated with various activators for 24 h, and total RNA was extracted for Northern blot analysis. Activators used included 3-isobutyl-1-methylxathine (IBMX, 10 µM) (Sigma) (24), Sp-Adenosine-3', 5'-cyclic monophosphorothioate (Sp-cAMPss) (10 µM) (BIOMOL Research Laboratories, Inc., Plymouth, PA) (25) or forskolin (FSK, 10 µM) (Sigma) (26) for activating the PKA pathway, and phorbol 12, 13-dibutyrate (PDBu 10 ng/ml) (BIOMOL Research Laboratories, Inc.) (27, 28, 29) and phorbol 12-myristate 13-acetate (PMA 10 µM) (BIOMOL Research Laboratories, Inc.) (27, 28, 29) for stimulating the PKC pathway.

Additionally, the effects of inhibitors of PKA/PKC pathways on BSP mRNA expression in the presence and absence of PTHrP were determined. Confluent cementoblasts were pretreated with an inhibitor for 12 h before treatment with either PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (10-7 M) or vehicle in the presence of the inhibitor for an additional 12 h. Total RNA was extracted and Northern blot analysis performed to determine the level of BSP mRNA. A cell-permeable adenylyl cyclase inhibitor, 9-(2-tetrahydrofuryl) adenine (THFA) (100 µM) (Sigma) (24, 30), was used to inhibit the activity of cAMP/PKA pathway, whereas GF109203X (3 µM) (BIOMOL Research Laboratories, Inc.) (31) was used to repress/block the PKC pathway.

Northern blot analysis
Total RNA was isolated from cells and quantitated by spectrophotometry as described (32). Ten micrograms of total RNA was electrophoresed on 1.2% agarose-formaldehyde gels, blotted to Duralon-UV membranes Stratagene, La Jolla, CA), and immobilized by UV light, using Stratagene’s Stratalinker. The membranes were hybridized with a labeled cDNA probe. The probes were labeled with {alpha}-32P-dCTP (Amersham Pharmacia Biotech, Arlington Heights, IL) using a Rediprime labeling kit (Amersham Pharmacia Biotech). After hybridization and washing, blots were exposed to Kodak X-OMAT film at -70 C with intensifying screens for 24–48 h. Blots were subsequently stripped and reprobed with either GAPDH and/or 18S rRNA cDNA probe to standardize RNA loading and hybridization efficiency. Blots were quantitatively scanned by a phosphoImager, Packard A2024 InstantImager (Downers Grove, IL); and the signals were normalized by calculating the ratio of signal intensities of the assayed markers vs. either the internal control GAPDH mRNA or 18S rRNA. For most of the studies, GAPDH and/or 18S rRNA were used for normalization and to rule out possible nonspecific effects of agents used. No differences were noted for using GAPDH vs. 18S rRNA. Therefore, in some experiments, GAPDH data are presented, whereas in other situations 18S rRNA was presented. Probes used included: 1) a mouse BSP cDNA probe cloned into PCR II vector (33); 2) a 1100 bp chicken GAPDH cDNA cloned into pGEM3 (34); and 3) an 18S rRNA cDNA in PBR 322 (35).

Western immunoblot analysis
The procedures were described previously (36). Briefly, cells were plated at a density of 5 x 104 cells/cm2 in 60-mm culture plates and incubated in DMEM containing 10% FBS. On reaching confluence, media were removed and cells were exposed to either vehicle or 10-7 M hPTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) for 24 h in serum-free DMEM. Conditioned media were collected, lyophilized, and subsequently dissolved in 1x SDS-PAGE loading buffer. A 10 µg aliquot of protein was fractionated by SDS-PAGE. LF-6 anti-BSP antibody (37), diluted at a ratio of 1:1000, was used to detect BSP protein. A secondary antibody (horseradish peroxidase-conjugated goat antirabbit immunoglobin G) was used at a dilution of 1: 10,000. Hybridization with antibodies was performed as previously reported (38). Immunoreactivity was determined by an enhanced chemiluminescence reaction assay (Amersham Pharmacia Biotech).

Adenylyl cyclase stimulation assay
Adenylyl cyclase stimulation assays were performed as described previously (39). Briefly, the OC-CM 30 cells were plated in DMEM media in 24-well tissue culture plates in triplicate, at 5 x 104 cells/cm2. At confluence, cells were stimulated with either vehicle, or PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31), or (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) or (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (Bachem California, Inc.) for 15 min at 37 C in calcium- and magnesium-free HBSS (Life Technologies, Inc.) containing 0.1% BSA and 1 mM IBMX (Sigma), a phosphodiesterase inhibitor. Intracellular cAMP was extracted and measured, using a cAMP binding protein assay (39). The cAMP levels were calculated by a log-logit method (Graph Pad Prism, normalized to cell number, and expressed as pmol/105 cells.

In vitro mineralization assay
The in vitro mineralization assay was performed as reported previously (40). Cells were plated at 5 x 104 cells/cm2 in 24-well plates with DMEM containing 10% FBS and supplemented with 50 µg/ml ascorbic acid. When cell reached confluence, designated day 0, medium was removed and cells were incubated in mineralization media (ascorbic acid-free {alpha}-MEM) (Life Technologies, Inc.) containing 10% FBS and supplemented with 50 µg/ml ascorbic acid) for 7 days, with inorganic phosphate (3 mM) added on day 6, to induce mineral nodule formation. Samples were processed on day 7 and von Kossa staining used to detect mineral nodule formation. To determine the effect of various agents on cementoblast-mediated mineralization, either vehicle or test agent was added to cultures on day 6. On day 7, samples were assayed for mineral deposition.

Statistical analysis
All experiments were performed a minimum of two times with comparable findings obtained. For cAMP stimulation assays, a Student’s t test was conducted to analyze the results (Instat 2.0, GraphPad Software, Inc., San Diego, CA). For mRNA decay rate measurements, the data were analyzed by either ANOVA followed by a Tukey-Kramer multiple comparison test and a Student’s t test as needed. For Northern blot analyses, representative autoradiographs are shown with a graphical analysis demonstrating statistical evaluation of multiple assays.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Dose-dependent inhibitory effect of PTHrP on BSP gene expression
Northern blot analysis demonstrated that PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) exhibited a dose-dependent inhibition of BSP mRNA expression in cementoblasts; a significant inhibitory effect was first detected at 10-9 M (P < 0.001) with a greater magnitude of inhibition associated with higher concentrations (10-8, 10-7, and 10-6 M) of PTHrP (Fig. 1Go, A and B). Given that BSP protein has been implicated in initiating biomineralization (18, 20, 41), the ability of PTHrP at these same concentrations to regulate cementoblast-mediated biomineralization also was determined. As revealed by a von Kossa assay, PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) abolished cementoblast-induced formation of mineralized nodules in a dose-dependent fashion with the first detectable inhibition of mineralization noted at 10-9 M (Fig. 1CGo). Furthermore, the dose-dependent profile of PTHrP effects on both BSP gene expression and biomineralization were consistent with the dose-dependent effect of PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) on elevating cAMP synthesis in cementoblasts (Fig. 1DGo and Ref. 15).



View larger version (39K):
[in this window]
[in a new window]
  		Figure 1. Dose-dependent effects of PTHrP on cementoblast activities. A, A representative Northern blot autoradiograph of BSP mRNA and 18S rRNA levels associated with 24 h PTHrP treatment at concentrations ranging from 10-13 M to 10-6 M. BSP mRNA of murine cementoblasts runs slightly above 18S rRNA with sizes approximating 2.0 kb. B, Graphical analysis of cpm (mean values expressed as BSP mRNA normalized to 18S rRNA ± SD). PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) exhibited a dose-dependent inhibitory effect on BSP gene expression by cementoblasts; and compared with vehicle (V), PTHrP at doses from 10-9 M to 10-6 M, significantly down-regulated BSP mRNA levels (* P < 0.001 vs. vehicle). The experiments were performed twice in duplicate with similar results noted. C, Dose-dependent effect of PTHrP on cementoblast-mediated biomineralization, in vitro. When cultured for 7 days in the presence of ascorbic acid (50 µg/ml) and incubated for the last 24 h with 3.0 mM inorganic phosphate (Pi), vehicle-treated cementoblasts promoted mineral nodule formation. However, when present for the last 24 h, PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) blocked mineralization in a dose-dependent manner with a dose as low as 10-9 M having an inhibitory effect. This experiment was performed twice in duplicate with comparable results obtained. D, PTHrP dose-dependent cAMP response: cementoblasts were exposed to PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) at increasing concentrations ranging from 10-11 M to 10-6 M for 15 min. cAMP levels were measured by a cAMP stimulation assay and the values were expressed as the mean ± SEM pmol cAMP/105 cells. PTHrP significantly stimulated cAMP elevation in cementoblasts in a dose-dependent manner (* P < 0.001 significance vs. basal level of cAMP). Experiments were performed three times with similar results noted.

 
Time course of PTHrP-induced inhibition of BSP mRNA
The temporal effect of PTHrP on BSP gene expression in cementoblasts was determined. Cementoblasts were exposed to either vehicle or 10-7 M PTHrP for the designated time intervals up to 24 h and BSP mRNA levels were determined by Northern blot analysis. As demonstrated in Fig. 2Go, a detectable inhibition of BSP mRNA (P < 0.001) was first noted at 6 h, with more prominent inhibition noted at 12 and 24 h.



View larger version (61K):
[in this window]
[in a new window]
  		Figure 2. Time-dependent effect of PTHrP on BSP mRNA expression by cementoblasts. Cementoblasts were plated at an initial density of 5 x 104 cells/cm2. At confluence, designated as 0 h, either vehicle (V) or PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) (10-7 M) (P) was added followed by isolation of total RNA at designated time points (0, 2, 6, 12, 24 h). A, A representative Northern blot autoradiograph of BSP mRNA and 18S rRNA levels. 18S rRNA hybridization is shown to demonstrate relative loading and blotting efficiency. B, Graphical analysis of BSP mRNA levels. Plot of cpm (mean values expressed as BSP mRNA normalized to 18S rRNA ± SD). Compared with vehicle, PTHrP significantly down regulated BSP mRNA levels at 6, 12, and 24 h (* P < 0.001). The experiments were performed four times with similar results observed.

 
Effect of PTHrP on BSP protein synthesis
To determine whether alterations in BSP protein levels in PTHrP-treated cementoblasts correlated with changes in mRNA levels, the effect of PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) on BSP protein synthesis was examined. Cementoblasts were treated with 10-7 M PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) for 24 h. Western blot analysis revealed that, in comparison to vehicle, PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) dramatically reduced BSP protein levels, correlating with the inhibitory effect of PTHrP on BSP mRNA expression (Fig. 3Go).



View larger version (44K):
[in this window]
[in a new window]
  		Figure 3. Effect of PTHrP on BSP protein level in cementoblasts. Confluent cementoblasts were treated with either vehicle or 10-7 M PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) for 24 h in serum-free DMEM media. Media were collected and BSP protein levels were measured by Western blot analysis as described in Materials and Methods section. MC3T3E1 cell conditioned medium served as a positive control. The size of the BSP protein is approximately 70 kDa. Experiments were done twice with one performed in duplicate.

 
Effect of cycloheximide on PTHrP-mediated inhibition of BSP mRNA expression
To determine whether the effect of PTHrP on BSP mRNA expression required protein synthesis, cycloheximide (10 µg/ml) (21), a protein synthesis inhibitor, was used. Confluent cementoblasts were treated with vehicle, PTHrP, PTHrP plus cycloheximide, or cycloheximide alone for 9 h. As illustrated in Fig. 4Go, PTHrP significantly decreased BSP mRNA expression (1 P < 0.001 vs. vehicle). In contrast, cycloheximide partially (** P < 0.05 vs. vehicle) but significantly reversed the PTHrP-mediated inhibition of BSP gene expression (*** P < 0.01 vs. PTHrP only). Cells exposed to cycloheximide for 9 h did not exhibit any visible morphological changes.



View larger version (44K):
[in this window]
[in a new window]
  		Figure 4. Effect of cycloheximide on PTHrP-mediated BSP mRNA down-regulation. Confluent cementoblasts were treated for 9 h with either vehicle (V), or PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) (10-7 M), or PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) (10-7 M) plus cycloheximide (cyclo. 10 µg/ml), or cycloheximide (10 µg/ml) alone, followed by total RNA extraction and Northern blot analysis. A, A representative Northern blot autoradiograph of BSP mRNA and 18S rRNA levels. B, Graphic analysis of normalized BSP mRNA levels. Values are expressed as mean values of the normalized BSP mRNA vs. 18S rRNA ± SD. The BSP mRNA levels were significantly reduced in PTHrP- and PTHrP plus cycloheximide-treated groups (* P < 0.001 for PTHrP vs. vehicle control and ** P < 0.05 for PTHrP plus cycloheximide vs. vehicle control). Nevertheless, cycloheximide significantly reversed the PTHrP-mediated repression of BSP gene expression (*** P < 0.01 for PTHrP plus cycloheximide vs. PTHrP). Experiments were performed in duplicate on two separate occasions with similar results observed.

 
Effect of actinomycin D on PTHrP-mediated inhibition of BSP mRNA
Inhibition of BSP gene expression can result from inhibition of transcription and/or an increase in mRNA degradation. To investigate whether reduction in BSP mRNA level resulted from a decrease in BSP mRNA stability, the decay rates of BSP mRNA associated with vehicle and PTHrP treatments were determined. As illustrated in Fig. 5Go, in untreated cells, BSP mRNA remained stable over a 12-h time period. In the presence of the transcriptional inhibitor actinomycin (Act D), the BSP mRNA decay curves for the vehicle- and PTHrP-treated samples revealed the half-life of BSP mRNA was approximately 6.5 and 7.2 h for vehicle- and PTHrP-treated groups, respectively. Statistical analysis revealed no difference in BSP mRNA decay rate between these two groups (P > 0.5).



View larger version (23K):
[in this window]
[in a new window]
  		Figure 5. Effect of actinomycin D on PTHrP-mediated inhibition of BSP gene expression. BSP mRNA stability was analyzed in the presence and absence of PTHrP. Cementoblasts were pretreated with either vehicle or PTHrP (10-7 M) for 6 h. Media were then changed (designated as 0 h) and the cementoblasts were treated with either vehicle or PTHrP (10-7 M) in either the presence or the absence of actinomycin D for designated time intervals. Total RNA was extracted at 0, 3, 6, 9, and 12 h and Northern analyses performed to detect BSP gene expression. y-axis, Log of mean values of BSP mRNA vs. 18S rRNA ± SD. Line V, The basal level BSP gene expression in the absence of transcription inhibitor actinomycin D; line V+Act. D, the decay curve of BSP mRNA in vehicle-treated group with a half-life (t1/2) of 6.5 h in the presence of actinomycin D; line PTHrP, PTHrP-mediated down-regulation of BSP gene expression in the absence of actinomycin D; line PTHrP+Act. D, the decay curve of BSP mRNA in PTHrP-treated group with a half-life (t1/2) of 7.2 h in the presence of actinomycin D. Experiments were performed in duplicate on two separate occasions with similar results observed. Statistical analyses revealed no significant difference in BSP mRNA decay rate between vehicle- and PTHrP-treated group (P > 0.5).

 
Effect of PTHrP analogs on BSP gene expression
PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) activates both the cAMP/protein kinase A (PKA) and protein kinase C (PKC) pathways (12). Based on the finding that PTHrP exhibited a similar dose-dependent profile in inhibiting BSP gene expression and in stimulating cAMP levels in cementoblasts (Fig. 1Go), it was hypothesized that the cAMP-dependent PKA pathway played a dominant role in mediating the inhibitory effect of PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) on BSP gene expression. As an initial strategy to test this hypothesis, the effect of PTHrP analogs on steady-state BSP mRNA levels in cementoblasts was investigated. Results indicated that PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31), reported to activate the PKA cascade only (23), mimicked PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) in inhibiting BSP gene expression (Fig. 6Go, A and B) (1 P < 0.001), in stimulating cAMP levels (Fig. 6CGo) (1 P < 0.001), and in blocking cementoblast-mediated mineralization (Fig. 6CGo). In contrast, PTHrP (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34), an antagonist for PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (23), failed to stimulate cAMP levels (Fig. 6CGo), repress BSP mRNA expression (Fig. 6AGo), and block biomineralization (Fig. 6DGo). Instead, PTHrP (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) promoted BSP gene expression when compared with vehicle (Fig. 6Go, A and B) (** P < 0.01).



View larger version (29K):
[in this window]
[in a new window]
  		Figure 6. Effects of PTHrP analogs on cementoblast activities. A and B, Role of PTHrP analogs in regulating BSP gene expression. Confluent cementoblasts were treated with either vehicle (V) or different PTHrP analogs at 10-7 M for 24 h and total RNA was extracted to measure the steady-state BSP mRNA levels using Northern blot analysis. A, A representative Northern blot analysis autoradiograph of BSP mRNA and GAPDH mRNA levels. B, Plot of cpm (mean values expressed as BSP mRNA vs. GAPDH mRNA ± SD). PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 ) and (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) significantly reduced BSP mRNA level (* P < 0.001 vs. vehicle), whereas PTHrP (7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) promoted BSP mRNA expression (** P < 0.01 vs. vehicle). C, Effect of PTHrP analogs on cAMP synthesis: Cementoblasts were stimulated with either 10-7 M of either PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 ), or (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ), or (7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) for 15 min. cAMP levels were measured as described in the Materials and Methods section. PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 ) and (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) significantly stimulated cAMP levels in cementoblasts (* P < 0.001 vs. vehicle), whereas PTHrP (7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) did not increase cAMP levels. Experiments were performed three times with similar results noted. D, Effect of PTHrP analogs on cementoblast-mediated biomineralization, in vitro. When cultured for 7 days in the presence of ascorbic acid and incubated for the last 24 h with inorganic phosphate (Pi; 3 mM), cementoblasts promoted mineral nodule formation. PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 ) and (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) at 10-7 M, when present for the last day, blocked mineralization. In contrast, PTHrP (7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) at 10-7 M did not prevent mineral nodule formation under similar treatment conditions. The experiment was performed three times. C, negative control without A. A, Induction; V, vehicle plus A. A; 1–31, PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ); 1–34, PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ); 7–34, PTHrP (7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ).

 
Effects of second message modulators of PKA/PKC pathways on BSP mRNA
As an additional strategy to elucidate the signal transduction pathway(s) involved, the effects of the PKA/PKC pathway activators on BSP gene expression were examined. IBMX (a phosphodiesterase inhibitor) (24), forskolin (a cAMP synthesis activator) (26), and Sp-cAMPss (a cAMP analog) (25), were used to activate the PKA pathway. The phorbol 12, 13-dibutyrate (PDBu) and phorbol 12-myristate 13-acetate (PMA), two phorbol esters that dramatically increase the affinity of PKC for Ca2+ resulting in its full activation (27, 28, 29), were employed to stimulate the PKC pathway. As illustrated in Fig. 7Go, A and B, mimicking the effect of PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) on cementoblasts, IBMX (1 mM), Sp-cAMPss (10 µM), and FSK (10 µM) reduced BSP mRNA levels to approximately 35%, 23%, and 2% of their basal levels, respectively (1 P < 0.001). In contrast, PMA and PDBu were ineffective in inhibiting steady-state BSP mRNA; instead, they up-regulated BSP mRNA by approximately 1.8- and 1.9-fold, respectively (** P < 0.01). In addition, the effect of PKA/PKC activators on BSP mRNA levels correlated with their action on cementoblast-mediated biomineralization, in vitro. FSK not only reduced BSP gene expression but also abolished formation of mineral nodules in cementoblast cultures (Fig. 7CGo), whereas PDBu failed to inhibit biomineralization (Fig. 7CGo) as it failed to decrease BSP gene expression (Fig. 7Go, A and B).



View larger version (45K):
[in this window]
[in a new window]
  		Figure 7. Effect of PKA/PKC pathway activators on cementoblast activities. A and B, Roles of PKA/PKC pathway activators in regulating steady-state BSP mRNA levels. A, Representative autoradiographs of Northern blot analysis: GAPDH was used to standardize RNA loading. B, A plot of mean values of relative expression of BSP mRNA vs. GAPDH mRNA ± SD. The activators of the PKA pathway, IBMX (10 mM), Sp-cAMPss (10 µM) and forskolin (10 µM) significantly decreased BSP mRNA expression. In contrast, the activators of the PKC pathway, PDBu (100 ng/ml) and PMA (100 nM), promoted BSP gene expression by approximately 1.8- and 1.9-fold, respectively (** P < 0.01 vs. vehicle). IBMX, 3-isobutyl-1-methylxanthine; PDBu, phorbol 12, 13-dibutyrate; PMA, phorbol 12-myristate 13-acetate. C, Effects of activators on cementoblast-mediated biomineralization, in vitro. Twenty-four-hour treatment with forskolin (10-5 M) abolished formation of mineral nodules in cementoblast cultures. In contrast, PDBu (100 ng/ml) did not inhibit mineralization under the similar treatment condition. V, Vehicle. Experiments were performed three times with similar results observed.

 
To confirm the involvement of PKA/PKC pathway(s), the ability of specific inhibitors of the PKA/PKC pathway to affect PTHrP action on BSP gene expression was evaluated. Consistent with the inhibitory role of cAMP/PKA stimulators, such as IBMX, Sp-cAMPss and forskolin, on BSP mRNA expression, 12 h pretreatment with a cell-permeable adenylate cyclase inhibitor THFA (24, 30) partially but significantly rescued PTHrP-induced down-regulation of the BSP transcripts (Fig. 8Go) (** P < 0.01). Furthermore, THFA alone, compared with vehicle, elevated the steady-state mRNA levels by 1.7-fold (*** P < 0.01) (Fig. 8Go, A and B). In marked contrast, 12 h-pretreatment with GF109203X, an aminoalkyl bisindolylmaleimide that potently and selectively inhibits PKC activity (31), failed to prevent PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)-mediated down-regulation of BSP gene expression (1 P < 0.001) (Fig. 8Go, C and D). Furthermore, 24 h-treatment with GF109203X alone dramatically reduced the basal level of BSP mRNA by approximately 80% (1 P < 0.001) (Fig. 8Go, C and D).



View larger version (30K):
[in this window]
[in a new window]
  		Figure 8. Effect of the PKA/PKC pathway inhibitors on PTHrP-mediated repression of BSP mRNA expression. Cementoblasts were pretreated with THFA, an adenylate cyclase inhibitor, or GF109203X, a PKC pathway inhibitor, for 12 h in before the stimulation with PTHrP (1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) (10-7 M) plus the inhibitors for an additional 12 h. A and C, Representative Northern blot autoradiographs of BSP and 18S rRNA of the experiments using inhibitors of PKA and PKC pathways, respectively. B and D, Graphic analysis of cpm (mean values expressed as BSP mRNA normalized to 18S rRNA level ± SD). PTHrP significantly inhibited BSP mRNA gene expression (* P < 0.001 vs. vehicle). THFA, partially but significantly, rescued PTHrP-induced down-regulation of BSP mRNA level (** P < 0.01 for PTHrP plus THFA vs. PTHrP only). Twenty-four-hour treatment with THFA alone significantly stimulated BSP approximately 1.7-fold (*** P < 0.01 vs. vehicle). In contrast, GF109203X failed to prevent PTHrP-induced BSP down-regulation. Furthermore, the inhibitor alone significantly reduced BSP mRNA level (* P < 0.001 vs. vehicle).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The role of PTHrP in regulating cells associated with cartilage and bone has been studied extensively both in vivo and in vitro (42, 43). In contrast, the function of PTHrP in controlling activities of cells associated with mineralized tissues of the tooth, such as cementum, has not been investigated in-depth due to lack of suitable model systems, such as in vitro cell lines. Understanding PTHrP’s function in cells associated with teeth is important for broadening our knowledge of the regulatory role of PTHrP during formation and regeneration of all mineralized tissues. The current studies, using well-defined murine cementoblast cell lines, explored the molecular mechanisms underlying the inhibitory effect of PTHrP on cementoblast activities.

The time course experiment revealed that a minimum of 6 h exposure of cells to PTHrP was required to observe an inhibitory effect on BSP mRNA expression. This pattern indicates that inhibition of BSP mRNA expression in cementoblasts is a secondary response requiring protein synthesis, as confirmed by the experiments using cycloheximide.

Effects of PTH/PTHrP on gene markers associated with mineralized tissues have been linked to transcriptional (24, 26, 44), and/or posttranscriptional (45) events. Data from the current studies suggest that the inhibitory effect of PTHrP on BSP mRNA expression in cementoblasts is at the transcription level. The mRNA decay curves revealed that when the transcription inhibitor actinomycin D was included, BSP mRNA in the vehicle-treated group decayed with a half-life of 6.5 h approximately, and the transcripts in PTHrP-pretreated cells decayed with a half-life of 7.2 h. In three different experiments, a slightly upward trend was noted for the BSP mRNA decay curve of PTHrP-treated group, compared with that of vehicle-treated group; however, no statistical difference in BSP mRNA decay rate was detected between the groups, suggesting that PTHrP did not dramatically affect the stability of BSP mRNA. Thus, the PTHrP-mediated down-regulation of BSP mRNA must result from transcriptional inhibition.

PTHrP stimulates both cAMP/PKA and PKC pathways (12, 46). The data presented in the current study suggested that the inhibitory effect of PTHrP on BSP mRNA expression in cementoblasts was mediated through the cAMP/PKA pathway, but not through the PKC pathway. First, the dose-dependent profile of PTHrP-mediated inhibition of BSP gene expression and biomineralization resembles the dose-dependent effect of PTHrP on promotion of cAMP levels in cementoblasts. Second, only the PTHrP analog capable of stimulating a cAMP response [PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)] (47) inhibited BSP gene expression and biomineralization. In contrast, PTHrP (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34), an antagonist for PTHrP (23, 48) failed to inhibit gene expression and biomineralization in cementoblast cultures. Third, other activators of the cAMP/PKA pathway, IBMX (a cAMP phosphodiesterase inhibitor) (24), forskolin (an adenylyl cyclase stimulator) (26), and Sp-cAMPs (a potent and specific activator for cAMP-dependent protein kinase A with excellent cell permeability and resistance to cyclic nucleotide phosphodiesterase) (25), mimicked the inhibitory effects of PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) on BSP gene expression and biomineralization, whereas two PKC activators, PMA and PDBU, which stimulate PKC function by binding to PKC and increasing its affinity to calcium (27, 28, 29), failed to do so. Finally, THFA, an adenylate cyclase inhibitor (24), partially but significantly blocked the effect of PTHrP on BSP gene expression, and THFA alone stimulated basal level BSP mRNA expression. In contrast, the PKC inhibitor, GF109203X (31), did not reverse PTHrP-mediated down-regulation of BSP mRNA expression, but, in fact, dramatically lowered the basal BSP mRNA level. Collectively, these results suggest that the cAMP/PKA pathway, but not the PKC pathway, mediates the inhibitory effect of PTHrP on BSP mRNA expression. Furthermore, it appears that this pathway may also play an inhibitory role in regulating the basal BSP gene expression. In support to this conclusion, Wang et al. reported that treatment of osteoblasts with forskolin blocked apatite deposition and decreased BSP mRNA expression (49).

In contrast to the inhibitory effects of the cAMP/PKA, the activation of the PKC pathway resulted in an increase of BSP gene expression in cementoblasts. PTHrP (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) is widely accepted as an effective antagonist for PTH/PTHrP functions (23, 30). Thus, the up-regulation of BSP mRNA expression might result form the PTHrP (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)-mediated inhibition of endogenous PTHrP. However, endogenous PTHrP mRNA and protein were not detected in the cementoblasts used for these studies (data not shown). Moreover, PTH (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) did not further decrease the basal cAMP level in cementoblasts (Fig. 6CGo). Therefore, this is not a likely explanation. Instead, stimulation of the PKC pathway may directly target a PKC-responsive element in the murine cementoblast BSP gene. This hypothesis is supported by the finding that the avian BSP gene contains a PKC-responsive cis-element in the promoter region (26) and the strong homology between the murine and avian promoter. Although this PKC-responsive element did not mediate the up-regulation of avian BSP mRNA expression associated with short-term exposure to PTH (26), it provides a potential mechanism by which cells regulate BSP gene expression in response to signals capable of modulating PKC activity (26). Identification of this sequence in the murine BSP gene and establishment of its function are critical for proving the validity of the latter hypothesis and for elucidating the mechanisms underlying the PKC pathway regulation of the cementoblast and/or osteoblast activities.

In striking contrast to the PTHrP-mediated down-regulation of BSP gene expression in murine cementoblasts, a PTH-mediated up-regulation of BSP mRNA level was reported in avian primary osteoblasts and was shown to be a primary and fast response by Yang et al. (26). More interestingly, this effect was also mainly through the cAMP/PKA pathway (26). Furthermore, CRE site(s) within the promoter regions were implicated as sites critical and responsible for this response (26). These data suggest that, at least, in part, the anabolic effect associated with PTH/PTHrP lies in the ability of the cAMP/PKA pathway to directly phosphorylate the preexisting transcription factors, such as CREB and/or ATF families (26, 50), and consequently, to stimulate transcription of down-stream genes containing corresponding CRE cis-elements, such as BSP (26). In contrast, our current studies demonstrated that inhibition of BSP gene expression in cementoblasts by PTHrP (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) is a secondary response dependent on protein synthesis and also mediated via the cAMP/PKA pathway. Therefore, the opposing effects of PTH/PTHrP on BSP mRNA expression reported by Yang’s investigation vs. the current studies might result from molecular controls down-stream from cAMP/PKA. A recent investigation by Tintut et al. (51) provides some insights into the potential down-stream regulation mechanisms that may be involved in PTHrP-mediated BSP mRNA down-regulation. Tintut et al. reported (51) that exposure of osteoblasts to cAMP/PKA agonists resulted in an inhibition of the osteoblast specific transcription factor 2 (Osf2)/core binding factor a1 (Cbfa1) considered a master regulator of osteoblast differentiation (52), and this effect was mediated through the cAMP/PKA-induced activation of the ubiquitin/ proteasome pathway, resulting in proteolytic degradation of Osf2/Cbfa1. Thus, one possible explanation for the current observation is that the stimulation of cementoblasts with PTHrP, via the cAMP/PKA pathway, induces a secondary response(s), such as activation of the ubiquitin/proteasome protein degradation pathway, thereby affecting the activity of factors controlling BSP gene expression and consequently repressing BSP mRNA expression. Because the murine BSP promoter contains multiple cis-elements, including binding sites for CREB (26), Osf2, and other as yet unidentified factors (53), where many of these cis-elements are targets for PTH/PTHrP and the PKA pathway (26, 50, 51), it is conceivable that the ultimate effect of PTH/PTHrP on BSP gene expression is determined by a net outcome of cell’s integration of various signal transduction pathways triggered by PTH/PTHrP/PKA pathway. Obviously, the latter can largely be shaped by several factors, including species (e.g. avian vs. murine), cell differentiation stages (primary preosteoblasts vs. mature cementoblasts), and experimental conditions/treatment modalities (e.g. short-term vs. long-term), as noted between Yang et al.’s study and our current investigation. To prove the validity of the model provided above, factors mediating the PTHrP inhibition of BSP gene expression need to be identified. Given the current knowledge indicating that Osf2 plays unique roles in controlling the development of dental tissues, such as cementum (54), enamel (55), and dentin (55), Osf2 can be a potential candidate factor mediating this inhibition. However, based on our previous study indicating that Osf2 regulation of BSP may be complex and likely involves other factors (53, 56), it has to be emphasized that PTHrP may also target at certain other upstream molecular components required for BSP gene expression to achieve its inhibitory effect on BSP mRNA (56).

In summary, the current studies, together with our previous investigations (10, 15), demonstrate that PTHrP has inhibitory effects on cementoblast activities. In combination with the in vivo observation that PTHrP-deficient mice exhibit a failure of tooth eruption and ankylosis of cementum with surrounding alveolar bone (11), our data suggest that PTHrP serves as an important inhibitor for cementogenesis in vivo. This proposed role mirrors the well-established function of PTHrP in inhibiting chondrocyte differentiation and mineralization of cartilage during development (57). More importantly, the present studies suggest that these inhibitory effects are mainly mediated through the cAMP/PKA pathway, but not through the PKC pathway. In contrast, the PKC pathway is associated with anabolic activities, such as maintenance and enhancement of BSP mRNA expression in vitro.The opposing activities of the PKA/PKC pathways may constitute an important component of the regulatory mechanisms orchestrating cementum formation in vivo. Moreover, this information is instrumental for development of novel therapies targeting the PKA/PKC pathways, to achieve a complete and predictable regeneration of cementum and other mineralized tissues.


   Acknowledgments
 
The authors are indebted to Drs. Kate F. Barald and Paul H. Krebsbach for insight, advice, and proofreading this manuscript. We also thank Drs. Michael Ulher and Thomas J. Rosol for generously sharing the expertise on the PKA pathway and the cAMP binding protein, respectively.


   Footnotes
 
1 This work was supported by NIH Grants DE-37596, DE-12211, and DK-53904 and the Block Grant from the Horace Rackham School of Graduate Studies, at the University of Michigan. Back

Received April 27, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, Martin TJ 1987 Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 84:5048–5052[Abstract/Free Full Text]
  2. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, Hudson PJ, Martin TJ, Wood WI 1987 A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893–896[Abstract/Free Full Text]
  3. Martin TJ, Moseley JM, Williams ED 1997 Parathyroid hormone-related protein: hormone and cytokine. J Endocrinol 154:S23–37
  4. Henderson JE, Amizuka N, Warshawsky H, Biasotto D, Lanske BM, Goltzman D, Karaplis AC 1995 Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol 15:064–4075
  5. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg HM, Mulligan RC 1994 Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8:277–289[Abstract/Free Full Text]
  6. Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, Karperien M, Defize LHK, Ho C, Mulligan RC, Abou-Samra AB, Juppner H, Segre GV, Kronenberg HM 1996 PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:63–66[Abstract]
  7. Somerman MJ, Morrison GM, Alexander MB, Foster RA 1993 Structure and composition of cementum. In: Bowan W, Tabak L (eds.) Cariology of the 1990’s. University of Rochester Press, New York, pp 155–171
  8. Beck F, Tucci J, Russell A, Senior PV, Ferguson MW 1995 The expression of the gene coding for parathyroid hormone-related protein (PTHrP) during tooth development in the rat. Cell Tissue Res 280:283–290[Medline]
  9. Tenorio D, Hughes FJ 1996 An immunohistochemical investigation of the expression of parathyroid hormone receptors in rat cementoblasts. Arch Oral Biol 41:299–305[CrossRef][Medline]
  10. Ouyang H, McCauley LK, Berry JE, D’Ericco JA, Strayhorn CL, Somerman MJ 2000 Response of immortalized murine cementoblasts/periodontal ligament cells to parathyroid hormone and parathyroid hormone-related protein in vitro. Arch Oral Biol 45:293–303[CrossRef][Medline]
  11. Philbrick WM, Dreyer BE, Nakchbandi IA, Karaplis AC 1998 Parathyroid hormone-related protein is required for tooth eruption. Proc Natl Acad Sci USA 95:11846–11851[Abstract/Free Full Text]
  12. Morris S, Bilezikian J 1996 Signal transduction in bone physiology: messager systems for parathyroid hormone. In: Bilezikian J, Raisz L, Rodan G (eds) Principles of bone biology. Academic Press, San Diego, pp 1203–1215
  13. D’Errico JA, Berry JE, Ouyang H, Strayhorn CL, Windel JJ, Somerman MJ 2000 Employing a transgenic animal model to obtain cementoblasts in vitro. J Periodontol 71:63–72[CrossRef][Medline]
  14. D’Errico JA, Ouyang H, Berry JE, MacNeil RL, Strayhorn CL, Imperiale MJ, Harris NL, Goldberg H, Somerman MJ 1999 Immortalized cementoblasts and periodontal ligament cells in culture. Bone 25:39–47[Medline]
  15. Ouyang H, McCauley LK, Berry J, Saygin NE, Tokiyasu Y, Somerman MJ 2000 Parathyroid hormone-related protein regulates extracellular matrix gene expression in cementoblasts and inhibits cementoblast-mediated biomineralization, in vitro. J Bone Min Res 15:2140–2153[CrossRef][Medline]
  16. Sodek J, Chen J, Kasugai S, Nagata T, Zhang Q, McKee MD, Nanci A 1992 Sialoproteins in bone remodelling. In: Davidovitch Z (ed) The Biological Mechanisms of Tooth Movement and Craniofacial Adaption, Columbus, pp 127–136
  17. MacNeil RL, Sheng N, Strayhorn C, Fisher LW, Somerman MJ 1994 Bone sialoprotein is localized to the root surface during cementogenesis. J Bone Miner Res 9:1597–1606[Medline]
  18. Chen JK, Shapiro HS, Wrana JL, Reimers S, Heersche JN, Sodek J 1991 Localization of bone sialoprotein (BSP) expression to sites of mineralized tissue formation in fetal rat tissues by in situ hybridization. Matrix 11:133–143[Medline]
  19. Chen J, McCulloch CA, Sodek J 1993 Bone sialoprotein in developing porcine dental tissues: cellular expression and comparison of tissue localization with osteopontin and osteonectin. Arch Oral Biol 38:241–249[CrossRef][Medline]
  20. MacNeil RL, Berry JE, Strayhorn CL, Somerman MJ 1996 Expression of bone sialoprotein mRNA by cells lining the mouse tooth root during cementogenesis. Arch Oral Biol 41:827–835[CrossRef][Medline]
  21. Obrig TG, Culp WJ, McKeehan WL, Hardesty B 1971 The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol Chem 246:174–181[Abstract/Free Full Text]
  22. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T 1998 Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 273:8799–805[Abstract/Free Full Text]
  23. Fujimori A, Cheng SL, Avioli LV, Civitelli R 1992 Structure-function relationship of parathyroid hormone: activation of phospholipase-C, protein kinase-A and -C in osteosarcoma cells. Endocrinology 130:29–36[Abstract/Free Full Text]
  24. Yu XP, Chandrasekhar S 1997 Parathyroid hormone (PTH 1–34) regulation of rat osteocalcin gene transcription. Endocrinology 138:3085–3092[Abstract/Free Full Text]
  25. Richards MK, Marletta MA 1994 Characterization of neuronal nitric oxide synthase and a C415H mutant, purified from a baculovirus overexpression system. Biochemistry 33:14723–14732[CrossRef][Medline]
  26. Yang R, Gerstenfeld LC 1996 Signal transduction pathways mediating parathyroid hormone stimulation of bone sialoprotein gene expression in osteoblasts. J Biol Chem 271:29839–29846[Abstract/Free Full Text]
  27. Nishizuka Y 1984 Turnover of inositol phospholipids and signal transduction. Science 225:1365–1370[Abstract/Free Full Text]
  28. Nishizuka Y 1984 The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308:693–698[CrossRef][Medline]
  29. Nishizuka Y 1986 Studies and perspectives of protein kinase C. Science 233:305–312[Abstract/Free Full Text]
  30. Koh AJ, Beecher CA, Rosol TJ, McCauley LK 1999 3',5'-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology 140:3154–362[Abstract/Free Full Text]
  31. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F 1991 The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266:15771–15781[Abstract/Free Full Text]
  32. Xie WQ, Rothblum LI 1991 Rapid, small-scale RNA isolation from tissue culture cells. Biotechniques 11:324–327[Medline]
  33. Young MF, Ibaraki K, Kerr JM, Lyu MS, Kozak CA 1994 Murine bone sialoprotein (BSP): cDNA cloning, mRNA expression, and genetic mapping. Mamm Genome 5:108–111[CrossRef][Medline]
  34. Dugaiczyk A, Haron JA, Stone EM, Dennison OE, Rothblum KN, Schwartz RJ 1983 Cloning and sequencing of a deoxyribonucleic acid copy of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle. Biochemistry 22:1605–1613[CrossRef][Medline]
  35. Renkawitz R, Gerbi SA, Glatzer KH 1979 Ribosomal DNA of fly Sciara coprophila has a very small and homogeneous repeat unit. Mol Gen Genet 173:1–13[CrossRef][Medline]
  36. Wang D, Christensen K, Chawla K, Xiao GZ, Krebsbach PH, Franceschi RT 1999 Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 14:893–903[CrossRef][Medline]
  37. Fisher LW, Stubbs JT, 3rd, Young MF 1995 Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop Scand 266:61–65
  38. Winnard RG, Gerstenfeld LC, Toma CD, Franceschi RT 1995 Fibronectin gene expression, synthesis and accumulation during in vitro differentiation of chicken osteoblasts. J Bone Miner Res 10:1969–1977[Medline]
  39. McCauley LK, Koh AJ, Beecher CA, Cui Y, Rosol TJ, Franceschi RT 1996 PTH/PTHrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis. J Cell Biochem 61:638–647[CrossRef][Medline]
  40. Marsh ME, Munne AM, Vogel JJ, Cui Y, Franceschi RT 1995 Mineralization of bone-like extracellular matrix in the absence of functional osteoblasts. J Bone Miner Res 10:1635–1643[Medline]
  41. Sodek J, Chen J, Kasugai S, Nagata T, Ahang Q, McKee MD, Nanci A 1992 Elucidating the functions of bone sialoprotein and osteopontin in bone formation. In: Slavkin H, Price P (eds) Chemistry and Biology of Mineralized Tissues, Excerpta Medica ed., Amsterdam-New York, pp 297–307
  42. Moseley JM, Gillespie MT 1995 Parathyroid hormone-related protein. Crit Rev Clin Lab Sci 32:299–343[Medline]
  43. Moseley J, Martin T 1996 Parathyroid hormone-related protein: physiological actions. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, pp 363–375
  44. Noda M, Rodan GA 1989 Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J Cell Biol 108:713–718[Abstract/Free Full Text]
  45. Partridge NC, Dickson CA, Kopp K, Teitelbaum SL, Crouch EC, Kahn AJ 1989 Parathyroid hormone inhibits collagen synthesis at both ribonucleic acid and protein levels in rat osteogenic sarcoma cells. Mol Endocrinol 3:232–239[Abstract/Free Full Text]
  46. Partridge NC, Bloch SR, Pearman AT 1994 Signal transduction pathways mediating parathyroid hormone regulation of osteoblastic gene expression. J Cell Biochem 55:321–327[CrossRef][Medline]
  47. Jouishomme H, Whitfield JF, Gagnon L, Maclean S, Isaacs R, Chakravarthy B, Durkin J, Neugebauer W, Willick G, Rixon RH 1994 Further definition of the protein kinase C activation domain of the parathyroid hormone. J Bone Miner Res 9:943–949[Medline]
  48. Jouishomme H, Whitfield JF, Chakravarthy B, Durkin JP, Gagnon L, Isaacs RJ, MacLean S, Neugebauer W, Willick G, Rixon RH 1992 The protein kinase-C activation domain of the parathyroid hormone. Endocrinology 130:53–60[Abstract/Free Full Text]
  49. Wang A, Martin JA, Lembket LA, Midura RJ 2000 Reversible suppression of in vitro biomineralization by activation of protein kinase A. J Biol Chem 275:11082–11091[Abstract/Free Full Text]
  50. Foulkes NS, Borrelli E, Sassone-Corsi P 1991 CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 64:739–749[CrossRef][Medline]
  51. Tintut Y, Parhami F, Le V, Karsenty G, Demer LL 1999 Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem 274:28875–28879[Abstract/Free Full Text]
  52. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:677–80[CrossRef][Medline]
  53. Benson MD, Aubin JE, Xiao G, Thomas PE, Franceschi RT 1999 Cloning of a 2.5 kb murine bone sialoprotein promoter fragment and functional analysis of putative Osf2 binding sites. J Bone Miner Res 14:396–405[CrossRef][Medline]
  54. Jiang H, Sodek J, Karsenty G, Thomas H, Ranly D, Chen J 1999 Expression of core binding factor Osf2/Cbfa-1 and bone sialoprotein in tooth development. Mech Dev 81:169–173[CrossRef][Medline]
  55. D’Souza RN, Aberg T, Gaikwad J, Cavender A, Owen M, Karsenty G, Thesleff I 1999 Cbfa1 is required for epithelial-mesenchymal interactions regulating tooth development in mice. Development 126:2911–2920[Abstract]
  56. Benson MD, Bargeon JL, Xiao G, Thomas PE, Kim A, Cui Y, Franceschi RT 2000 Identification of a homeodomain binding element in the bone sialoprotein gene promoter that is required for its osteoblast-selective expression. J Biol Chem 275:13907–13917[Abstract/Free Full Text]
  57. Amizuka N, Warshawsky H, Henderson JE, Goltzman D, Karaplis AC 1994 Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol 126:1611–1623[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 EndocrinologyHome page
S. Yu, R. T. Franceschi, M. Luo, X. Zhang, D. Jiang, Y. Lai, Y. Jiang, J. Zhang, and G. Xiao
Parathyroid Hormone Increases Activating Transcription Factor 4 Expression and Activity in Osteoblasts: Requirement for Osteocalcin Gene Expression
Endocrinology, April 1, 2008; 149(4): 1960 - 1968.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
F.H. Nociti Jr., B.L. Foster, S.P. Barros, R.P. Darveau, and M.J. Somerman
Cementoblast Gene Expression is Regulated by Porphyromonas gingivalis Lipopolysaccharide Partially via Toll-like Receptor-4/MD-2
Journal of Dental Research, August 1, 2004; 83(8): 602 - 607.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Jiang, R. T. Franceschi, H. Boules, and G. Xiao
Parathyroid Hormone Induction of the Osteocalcin Gene: REQUIREMENT FOR AN OSTEOBLAST-SPECIFIC ELEMENT 1 SEQUENCE IN THE PROMOTER AND INVOLVEMENT OF MULTIPLE SIGNALING PATHWAYS
J. Biol. Chem., February 13, 2004; 279(7): 5329 - 5337.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
M. Zhao, J.E. Berry, and M.J. Somerman
Bone Morphogenetic Protein-2 Inhibits Differentiation and Mineralization of Cementoblasts in vitro
Journal of Dental Research, January 1, 2003; 82(1): 23 - 27.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Gopalakrishnan, H. Ouyang, M. J. Somerman, L. K. McCauley, and R. T. Franceschi
Matrix {gamma}-Carboxyglutamic Acid Protein Is a Key Regulator of PTH-Mediated Inhibition of Mineralization in MC3T3-E1 Osteoblast-Like Cells
Endocrinology, October 1, 2001; 142(10): 4379 - 4388.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ouyang, H.
Right arrow Articles by Somerman, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ouyang, H.
Right arrow Articles by Somerman, M. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals